The case study of GlaxoSmithKline (GSK) in China highlights the company's struggles with corruption allegations and its attempts to cooperate with Chinese authorities. Despite being a major player in the healthcare industry, GSK faced significant challenges due to the anti-corruption laws implemented by the Chinese government. The report emphasizes that the company is doing well currently, but future growth opportunities are uncertain. Additionally, it discusses the importance of understanding the cultural and environmental aspects of operating internationally.